Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
July 27, 2023 08:10 ET
|
Ayala Pharmaceuticals
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the first half of 2024 REHOVOT and TEL...
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
July 05, 2023 08:00 ET
|
Ayala Pharmaceuticals
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT,...
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 05, 2023 08:00 ET
|
Ayala Pharmaceuticals
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss...
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 17:05 ET
|
Ayala Pharmaceuticals
ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose) Tumor response,...
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 23, 2023 13:20 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023...
EQUITY ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Edgio, Inc. f/k/a Limelight Networks, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGIO, LLNW
April 27, 2023 12:23 ET
|
The Rosen Law Firm PA
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edgio,...
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023 08:00 ET
|
Ayala Pharmaceuticals
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it will present a...
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
April 04, 2023 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
HPV Associated Disorders Global Market Report 2023
April 04, 2023 07:21 ET
|
ReportLinker
New York, April 04, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "HPV Associated Disorders Global Market Report 2023" -...
New Innovations opens Prospects for the Cancer Vaccine Market, Propelling the Growth of Market at 12% CAGR through 2033 | Future Market Insights, Inc. Study
March 08, 2023 05:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 08, 2023 (GLOBE NEWSWIRE) -- The global Cancer Vaccine Market is expected to grow significantly in the coming years, according to a new report published by Future Market Insights....